Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
naveglitazar · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| naveglitazar | DRUG | - |
Inclusion Criteria: * Diagnosis of Type 2 Diabetes for at least 3 months. * Diabetes managed with diet and exercise alone or with either metformin or sulfonylurea alone as an adjunct to diet and exercise. * Diabetes therapy must be unchanged for at least 3 months prior to screening. * Females must ...
Naveglitazar is an investigational small molecule being developed for the treatment of non-insulin-dependent diabetes mellitus, also known as type 2 diabetes. It is intended as an oral antidiabetic agent. The drug is currently in clinical development and has not been approved by regulatory authorities.
Naveglitazar is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research on this investigational oral antidiabetic agent for the treatment of type 2 diabetes.
Naveglitazar is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied for the treatment of non-insulin-dependent diabetes mellitus, and its development is still in the clinical trial stage.
Naveglitazar has one completed clinical trial registered under NCT00065312, titled 'An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes.' This Phase 2 study was conducted in the United States and enrolled adults aged 18 years and older with non-insulin-dependent diabetes mellitus.
Naveglitazar is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of non-insulin-dependent diabetes mellitus. The drug has completed one clinical trial, but it remains under investigation and has not received marketing approval from regulatory authorities.